Dr. Clay Seigall is the President, Chief Executive Officer, and Chairman of the board of Seattle Genetics. Dr. Seigall co-founded Seattle Genetics in 1998. Seattle Genetics is a biotechnology company that is focused on developing antibody-based therapies in the treatment of cancer. They have one product on the market, Adcetris, and are presently in various stages of development of other products. Since 1998 the company has grown from over 100 employees to presently over 800.
Dr. Seigall received his Bachelors of Zoology from the University of Maryland. After that he attended George Washington University where he received his Ph.D. in Genetics. Upon graduation he worked for Bristol-Myers Squibb Pharmaceutical Research Institute for a number of years, as well as the National Cancer Institute, National Institutes of Health. It was after these careers that he decided to co-found his own company which is how Seattle Genetics came about.
Seattle Genetics is a cancer research and therapeutic drug development company. They focus on creating antibody-drug conjugates in order to treat cancer in patients. In addition to Adcetris, which they co-developed with Takeda Pharmaceutical Company Limited, they have more than 20 antibody-drug conjugates in development. The most advanced one currently is SGN-CD33A which is in the Phase 3, or advanced, stage of development.
As Chief Executive Officer of Seattle Genetics, Dr. Clay Siegall’s job is to manage the overall operations and resources of the company. A CEO sets the tone and vision of the company as well. As CEO he is also the person that handles communication between corporate operations and the Board of Directors.
Seattle Genetics and Dr. Clay Seigall have been featured in a number of media outlets. These outlets include The Seattle Times, Investor’s Business Daily, and the Puget Sound Business Journal. These articles discuss Seattle Genetics current drug offering, Adcetris, as well as their potential upcoming slate of drugs designed to treat cancer. In particular Investor’s Business Daily has a long Q&A session with Dr. Siegall that goes into his insights into cancer research and where the field is heading.